منابع مشابه
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
tuberculosis prevention, care and control after 2015. Geneva, WHO, 2014. 13 World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, WHO, 2013. 14 Van Deun A, Maug AK, Bola V, et al. Rifampicin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633–2640. 15 Salje H, Andrews JR, Deo S, et al. The impo...
متن کاملBedaquiline: finding the pores on the pot.
Division of Respiratory Medicine, Dept of Medicine, Gordon and Leslie Diamond Health Care Centre, Vancouver, BC, Canada. Snyder Institute for Chronic Diseases and Institute of Public Health, Depts of Medicine and Community Health Sciences, Calgary, AB, Canada. Dept of Physiology and Pharmacology, Dept of Immunology, Microbiology and Infectious Diseases, Health Sciences Centre, Calgary, AB, Canada.
متن کاملAcquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non-target based resistance to BDQ, and cross-resistance to clofazimine (CFZ), is due to mutations in Rv0678, a transcriptional repressor of the genes...
متن کاملIn vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria
Bedaquiline (BDQ) has been proven to be effective in the treatment of multidrug-resistant tuberculosis. We hypothesized that BDQ could be a potential agent to treat nontuberculous mycobacterial (NTM) infection. The objective of this study was to evaluate the in vitro activity of BDQ against rapidly growing mycobacteria by assessing the minimal inhibitory concentration (MIC) and minimal bacteric...
متن کاملIn Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
We performed bedaquiline broth microdilution susceptibility testing using Clinical and Laboratory Standards Institute (CLSI) guidelines on 103 respiratory isolates of Mycobacterium avium complex (MAC), including multidrug-resistant isolates. Approximately 90% of isolates had bedaquiline MICs of ≤0.008 μg/ml, and 102/103 isolates had MICs of ≤0.015 μg/ml. Bedaquiline has excellent potential for ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Clinical Pharmacology
سال: 2015
ISSN: 0306-5251
DOI: 10.1111/bcp.12613